Nuo is leveraging Aurix adoption and a Smith+Nephew private-label distribution agreement to drive revenue growth. The market is responding favorably to continued improvement in Medicare-related reimbursement for Aurix and a vastly changed overall reimbursement landscape. However, the company remains pre-profitability with significant financial constraints and ongoing dependence on debt financing to fund growth.
Cyborg Score Rationale
Strong Q1 2026 revenue growth (169% YoY) and improving gross margins demonstrate traction in the chronic wound care market. However, cash was only $263,827 at March 31, 2026 against current liabilities of about $1.4 million, creating significant liquidity pressure. The company secured $1.675 million in secured debt funding through May 2026 with 12% interest paid entirely in warrants, diluting equity significantly.
Top Insights
Q1 2026 revenues of $1.3M represented 169% growth over Q1 2025, with Aurix branded revenues up 30% sequentially versus Q4 2025.
Revenue growth was driven by Aurix adoption, new private-label sales, and $77,941 of Smith+Nephew distribution fee revenue (April 2025 partnership).
Improving Medicare reimbursement for Aurix and favorable market conditions support confidence in 2026 momentum.
Cash position of only $263,827 against $1.4M in current liabilities, with management stating substantial doubt about going concern ability, makes near-term capital raise essential.
Named Competitors
Arteriocyte — Point-of-care autologous platelet-rich plasma systems for wound care
Vivex Biologics — Regenerative medicine and tissue repair solutions
Smith+Nephew Wound Care — Advanced wound management and regenerative medicine products
Recent Developments
(May 2026) Secured $675,000 interim funding and expanded secured debt facility to $2.0 million total at 12% interest payable in warrants
(May 2026) Announced Q1 2026 results showing 169% revenue growth to $1.3 million with narrowing net loss to $446,000
(May 2026) Aurix system revenues increased 30% sequentially in Q1 2026 driven by private physician office adoption and improved Medicare reimbursement
Open the full interactive Nuo Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.